Impact of SARS-CoV-2 infection on respiratory viral immune responses in children with and without asthma
SARS-CoV-2 感染对患有和不患有哮喘的儿童呼吸道病毒免疫反应的影响
基本信息
- 批准号:10568344
- 负责人:
- 金额:$ 81.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-01 至 2028-06-30
- 项目状态:未结题
- 来源:
- 关键词:17q212019-nCoVATAC-seqAddressAdultAffectAgeAllelesAntibodiesAsthmaBindingBloodCOVID-19 outbreakCOVID-19 pandemicCOVID-19 vaccineCellsChildChildhoodChildhood AsthmaChronicClinicCommon Cold VirusDataDiseaseEnrollmentEpigenetic ProcessEpithelial CellsEthnic OriginFrequenciesGene ExpressionGeneticGenetic PolymorphismGenetic Predisposition to DiseaseGenetic VariationHematopoietic stem cellsImmuneImmune responseImmunologyImpairmentIncidenceInfectionInflammasomeInflammatoryInflammatory ResponseLinkMasksMembraneMetabolismMinorMonitorMucous MembraneNasal EpitheliumNew York CityNoseNuclearOutcomePathogenesisPeripheral Blood Mononuclear CellPharmaceutical PreparationsPrevalenceQuestionnairesRaceReactionReportingRespiratory syncytial virusRhinovirusRhinovirus infectionRisk FactorsSARS-CoV-2 B.1.1.529SARS-CoV-2 exposureSARS-CoV-2 infectionSARS-CoV-2 pathogenesisSARS-CoV-2 variantSamplingSeveritiesShapesSocial DistanceSphingolipidsStimulusT-LymphocyteTestingVDAC1 geneVaccinesVariantViralViral Respiratory Tract InfectionVirus DiseasesWheezingage groupage relatedairway epitheliumasthma exacerbationasthmaticchronic inflammatory diseasechronic respiratory diseasecohorthealth disparityimmunoregulationpandemic diseasepathogenic virusperipheral bloodpost SARS-CoV-2 infectionprogenitorprogramsprotective effectreceptor expressionrespiratoryrespiratory healthrespiratory infection virusrespiratory pathogenrespiratory virusresponserisk variantsevere COVID-19single-cell RNA sequencingsocioeconomicstranscriptomicsuptake
项目摘要
PROJECT SUMMARY
SARS-CoV-2 infections in children are mostly milder and less lethal than in adults. This lower
incidence of relevant disease associated with SARS-CoV-2 has surprisingly also been observed
for children with asthma, the most common chronic respiratory and inflammatory disease in
children. As social distancing and masks have dramatically but temporarily decreased the
spread of common viral respiratory infections, this created the positive effect of a significant
decrease of viral-triggered asthma in children. The growing prevalence of SARS-CoV-2 infection
in children and the resurgence of non-SARS-CoV-2 respiratory viral infections make it critical
and timely to understand how SARS-CoV-2 infection shapes respiratory outcomes and immune
responses to other respiratory viruses and the upcoming SARS-CoV-2 vaccines.
In addition to a strong genetic predisposition, asthma is strongly linked to viral respiratory
infections, and infectious stimuli can have long-term epigenetic consequences that shape
immune responses to subsequent infections. We propose that a common genetic variation that
alters sphingolipid levels in children with asthma may also result in limited pathogenesis of
SARS-CoV-2 in children with asthma. This proposal aims to test the hypothesis is that common
genetic variation in asthma moderate age-dependent outcomes and immune responses to
SARS-CoV-2 infection and vaccines utilizing an NYC pediatric asthma cohort that was started
early in the pandemic. This cohort is uniquely suited to the hypothesis as it (1) includes children
of all ages with and without asthma; (2) is enriched for children from ethnic, racial, and
socioeconomic backgrounds associated with health disparities and high exposure to SARS-
CoV-2; and (3) has already enrolled more than three hundred with a high antibody positivity rate
since May 2020. The availability of detailed questionnaire data on asthma and SARS-CoV-2
exposure, biospecimen that include blood (including stored PBMC), and nasal samples will
enable us to address these three Specific Aims, to (1) determine the age-dependent effect of
SARS-CoV-2 infection on subsequent respiratory health in asthmatic children; (2) define the
epigenetic and transcriptomic effect of SARS-CoV-2 infection on hematopoietic stem cells,
and (3) define the effects of common genetic asthma risk alleles on responses to SARS-CoV-2
infection of nasal epithelial cells and subsequent infection with respiratory syncytial virus and
rhinovirus. These studies will be supported by a team with expertise in viral immunology,
pediatric asthma, and epigenetics of immune responses and will inform on age- and disease-
specific impact and mechanisms of SARS-CoV-2 and common respiratory viruses in children.
项目摘要
SARS-CoV-2在儿童中的感染大多比成人温和,致命性较低。这种较低
还令人惊讶地观察到与SARS-CoV-2相关疾病的发病率
对于哮喘儿童,最常见的慢性呼吸道和炎症性疾病,
孩子随着社会距离和面具的急剧但暂时减少,
常见病毒性呼吸道感染的传播,这产生了显著的积极作用
减少儿童中病毒引发的哮喘。SARS-CoV-2感染的流行率不断上升
在儿童和非SARS-CoV-2呼吸道病毒感染的复苏,
及时了解SARS-CoV-2感染如何影响呼吸系统结果和免疫
对其他呼吸道病毒和即将到来的SARS-CoV-2疫苗的反应。
除了强烈的遗传倾向外,哮喘与病毒性呼吸道疾病密切相关。
感染和感染性刺激可以产生长期的表观遗传后果,
对后续感染的免疫反应。我们提出,一种常见的遗传变异,
哮喘儿童鞘脂水平的改变也可能导致哮喘的发病机制受到限制,
SARS-CoV-2在儿童哮喘中的应用这一提议旨在检验假设是否普遍
哮喘中的遗传变异中度年龄依赖性结果和免疫应答
SARS-CoV-2感染和疫苗使用纽约儿童哮喘队列,
在大流行的早期。这个队列是唯一适合的假设,因为它(1)包括儿童
所有年龄段的哮喘和非哮喘;(2)是丰富的儿童从种族,种族,
与健康差异和SARS高暴露率相关的社会经济背景-
CoV-2;(3)已经招募了300多人,抗体阳性率很高
自2020年5月以来。关于哮喘和SARS-CoV-2的详细问卷数据的可用性
暴露,包括血液(包括储存的PBMC)和鼻样本的生物标本将
使我们能够解决这三个具体目标,以(1)确定年龄依赖的影响,
SARS-CoV-2感染对哮喘儿童呼吸道健康的影响;(2)明确哮喘儿童的
SARS-CoV-2感染对造血干细胞的表观遗传学和转录组学影响,
以及(3)确定常见的遗传性哮喘风险等位基因对SARS-CoV-2应答的影响
鼻上皮细胞感染和随后的呼吸道合胞病毒感染,
鼻病毒这些研究将得到一个具有病毒免疫学专业知识的团队的支持,
儿童哮喘,免疫反应的表观遗传学,并将告知年龄和疾病-
SARS-CoV-2和常见呼吸道病毒对儿童的具体影响和机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stefan Worgall其他文献
Stefan Worgall的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Stefan Worgall', 18)}}的其他基金
Respiratory sphingolipid synthesis involved in airway hyperreactivity and viral-triggered asthma
呼吸鞘脂合成参与气道高反应性和病毒引发的哮喘
- 批准号:
10660726 - 财政年份:2023
- 资助金额:
$ 81.23万 - 项目类别:
Enhancing protective immunity against RSV by inhibitors of sphingolipid synthesis
通过鞘脂合成抑制剂增强对 RSV 的保护性免疫力
- 批准号:
10354486 - 财政年份:2022
- 资助金额:
$ 81.23万 - 项目类别:
Enhancing protective immunity against RSV by inhibitors of sphingolipid synthesis
通过鞘脂合成抑制剂增强对 RSV 的保护性免疫力
- 批准号:
10619550 - 财政年份:2022
- 资助金额:
$ 81.23万 - 项目类别:
Mucosal Immunization Against P. aeruginosa by Modified Adenovirus Vectors
改良腺病毒载体针对铜绿假单胞菌的粘膜免疫
- 批准号:
8662189 - 财政年份:2013
- 资助金额:
$ 81.23万 - 项目类别:
Mucosal Immunization Against P. aeruginosa by Modified Adenovirus Vectors
改良腺病毒载体针对铜绿假单胞菌的粘膜免疫
- 批准号:
9040866 - 财政年份:2013
- 资助金额:
$ 81.23万 - 项目类别:
Mucosal Immunization Against P. aeruginosa by Modified Adenovirus Vectors
改良腺病毒载体针对铜绿假单胞菌的粘膜免疫
- 批准号:
8579420 - 财政年份:2013
- 资助金额:
$ 81.23万 - 项目类别:
Vaccination Against RSV with Capsid-modified Ad Vectors
使用衣壳修饰的广告载体进行 RSV 疫苗接种
- 批准号:
7654470 - 财政年份:2009
- 资助金额:
$ 81.23万 - 项目类别:
Vaccination Against RSV with Capsid-modified Ad Vectors
使用衣壳修饰的广告载体进行 RSV 疫苗接种
- 批准号:
7847618 - 财政年份:2009
- 资助金额:
$ 81.23万 - 项目类别:
相似国自然基金
微米和纳米塑料作用下2019-nCoV抗病毒药物利巴韦林对河蚬的毒性作用机制
- 批准号:
- 批准年份:2021
- 资助金额:10.0 万元
- 项目类别:省市级项目
2019-nCoV感染导致人体淋巴细胞减低机制及其对机体免疫功能影响
- 批准号:82030002
- 批准年份:2020
- 资助金额:135 万元
- 项目类别:专项基金项目
基于人口流动大数据的新型冠状病毒(2019-nCoV)输出感染风险及接触网络传播模型研究
- 批准号:
- 批准年份:2020
- 资助金额:135 万元
- 项目类别:
新型冠状病毒(2019-nCoV)反向遗传系统及啮齿类感染模型的建立与应用
- 批准号:
- 批准年份:2020
- 资助金额:150 万元
- 项目类别:
云南驯养野生动物中新型冠状病毒(2019-nCoV)溯源调查与验证
- 批准号:
- 批准年份:2020
- 资助金额:140 万元
- 项目类别:
血必净预防2019-nCoV肺炎发生ARDS及机制研究
- 批准号:82041003
- 批准年份:2020
- 资助金额:135 万元
- 项目类别:专项基金项目
新型冠状病毒2019-nCoV复制复合体关键蛋白的功能与潜在药物靶点研究
- 批准号:
- 批准年份:2020
- 资助金额:150 万元
- 项目类别:专项基金项目
2019-nCoV蝙蝠及人群代表性流行株致病能力的比较研究
- 批准号:
- 批准年份:2020
- 资助金额:150 万元
- 项目类别:专项基金项目
人新型冠状病毒2019-nCoV受体利用介导的种间传播和感染机制研究
- 批准号:
- 批准年份:2020
- 资助金额:140 万元
- 项目类别:专项基金项目
2019-nCoV“不典型症状”感染者的宿主因素及其作用机制研究
- 批准号:
- 批准年份:2020
- 资助金额:150 万元
- 项目类别:专项基金项目
相似海外基金
COVID-19 Variant Supplement - Targeting programmed ribosomal frameshifting as a therapeutic strategy against 2019-nCoV
COVID-19 变异补充剂 - 以程序化核糖体移码为目标作为针对 2019-nCoV 的治疗策略
- 批准号:
443173 - 财政年份:2021
- 资助金额:
$ 81.23万 - 项目类别:
Operating Grants
Destigmatizing Chinese Communities in the face of 2019-nCoV: Emergency Management Actions to Address Social Vulnerability in Toronto and Nairobi
面对 2019-nCoV,消除华人社区的污名化:解决多伦多和内罗毕社会脆弱性的应急管理行动
- 批准号:
422610 - 财政年份:2020
- 资助金额:
$ 81.23万 - 项目类别:
Operating Grants
Task A38: Establishment of Small Animal Models for Screening Medical Countermeasures for the 2019 Novel Coronavirus (2019-nCoV)
任务A38:建立用于筛选2019新型冠状病毒(2019-nCoV)医疗对策的小动物模型
- 批准号:
10330359 - 财政年份:2020
- 资助金额:
$ 81.23万 - 项目类别:
Task A38: Establishment of Small Animal Models for Screening Medical Countermeasures for the 2019 Novel Coronavirus (2019-nCoV)
任务A38:建立用于筛选2019新型冠状病毒(2019-nCoV)医疗对策的小动物模型
- 批准号:
10454575 - 财政年份:2020
- 资助金额:
$ 81.23万 - 项目类别:
Task A38: Establishment of Small Animal Models for Screening Medical Countermeasures for the 2019 Novel Coronavirus (2019-nCoV)
任务A38:建立用于筛选2019新型冠状病毒(2019-nCoV)医疗对策的小动物模型
- 批准号:
10454574 - 财政年份:2020
- 资助金额:
$ 81.23万 - 项目类别:
Task A38: Establishment of Small Animal Models for Screening Medical Countermeasures for the 2019 Novel Coronavirus (2019-nCoV)
任务A38:建立用于筛选2019新型冠状病毒(2019-nCoV)医疗对策的小动物模型
- 批准号:
10579807 - 财政年份:2020
- 资助金额:
$ 81.23万 - 项目类别:
Targeting programmed ribosomal frameshifting as a therapeutic strategy against 2019-nCoV
以程序化核糖体移码为目标作为针对 2019-nCoV 的治疗策略
- 批准号:
422724 - 财政年份:2020
- 资助金额:
$ 81.23万 - 项目类别:
Operating Grants
Task A38: Establishment of Small Animal Models for Screening Medical Countermeasures for the 2019 Novel Coronavirus (2019-nCoV)
任务A38:建立用于筛选2019新型冠状病毒(2019-nCoV)医疗对策的小动物模型
- 批准号:
10464972 - 财政年份:2020
- 资助金额:
$ 81.23万 - 项目类别:
Task A38: Establishment of Small Animal Models for Screening MCMs for the 2019 Novel Coronavirus (2019-nCoV)
任务 A38:建立用于筛选 2019 年新型冠状病毒(2019-nCoV)的 MCM 的小动物模型
- 批准号:
10473626 - 财政年份:2020
- 资助金额:
$ 81.23万 - 项目类别:
RAPID Proposal: Psychological distance and risk perception related to the 2019 novel coronavirus (2019-nCoV) outbreak
RAPID提案:与2019年新型冠状病毒(2019-nCoV)爆发相关的心理距离和风险感知
- 批准号:
2020597 - 财政年份:2020
- 资助金额:
$ 81.23万 - 项目类别:
Standard Grant